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Abstract
Background: Acute appendicitis is one of the most common indications for emergency surgery. In patients with a
complex appendicitis, prolonged antibiotic prophylaxis is recommended after appendectomy. There is no consensus
regarding the optimum duration of antibiotics. Guidelines propose 3 to 7 days of treatment, but shorter courses may be
as effective in the prevention of infectious complications. At the same time, the global issue of increasing antimicrobial
resistance urges for optimization of antibiotic strategies. The aim of this study is to determine whether a short course
(48 h) of postoperative antibiotics is non-inferior to current standard practice of 5 days.
Methods: Patients of 8 years and older undergoing appendectomy for acute complex appendicitis – defined as a
gangrenous and/or perforated appendicitis or appendicitis in presence of an abscess – are eligible for inclusion.
Immunocompromised or pregnant patients are excluded, as well as patients with a contraindication to the study
antibiotics. In total, 1066 patients will be randomly allocated in a 1:1 ratio to the experimental treatment arm
(48 h of postoperative intravenously administered (IV) antibiotics) or the control arm (5 days of postoperative IV
antibiotics). After discharge from the hospital, patients participate in a productivity-cost-questionnaire at 4 weeks
and a standardized telephone follow-up at 90 days after appendectomy. The primary outcome is a composite
endpoint of infectious complications, including intra-abdominal abscess (IAA) and surgical site infection (SSI), and
mortality within 90 days after appendectomy. Secondary outcomes include IAA, SSI, restart of antibiotics, length of
hospital stay (LOS), reoperation, percutaneous drainage, readmission rate, and cost-effectiveness. The non-inferiority
margin for the difference in the primary endpoint rate is set at 7.5% (one-sided test at ɑ 0.025). Both per-protocol and
intention-to-treat analyses will be performed.
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Discussion: This trial will provide evidence on whether 48 h of postoperative antibiotics is non-inferior to a standard
course of 5 days of antibiotics. If non-inferiority is established, longer intravenous administration following
appendectomy for complex appendicitis can be abandoned, and guidelines need to be adjusted accordingly.
Trial registration: Dutch Trial Register, NTR6128. Registered on 20 December 2016.
Keywords: Acute appendicitis, Complex appendicitis, Antibiotic prophylaxis, .
Background
Acute appendicitis is one of the most common surgical
emergencies in children and adults worldwide [1–3].
Although the role of surgery as primary treatment has
recently been questioned, appendectomy remains the
treatment of choice [4, 5]. In the Netherlands, more
than 12,000 patients undergo appendectomy for acute
appendicitis each year [6]. In Northern America the
estimated number of patients with appendicitis in 2015
was over 378,000 [7]. Intraoperatively, acute appendicitis
is classified as either simple or complex. A phlegmonous
appendix is considered simple. A complex appendicitis
includes a gangrenous and/or perforated appendix as well
as any appendicitis with an intra-abdominal or pelvic ab-
scess (IAA) [8]. Previously, it was thought that a simple
appendicitis could progress towards a complex
appendicitis over time, but more recent data suggest
that both entities represent distinct types of inflammation
[8, 9]. Some 25–30% of all patients with appendicitis have
a complex appendicitis, which is associated with increased
risk of postoperative infectious complications [10–14].
Therefore, following perioperative antibiotic prophylaxis,
guidelines recommend postoperative antibiotics for com-
plex appendicitis [15–18].
Currently, there is no consensus on the duration of
postoperative antibiotic treatment and different antibiotic
regimens are used [8, 19–21]. A nationwide cohort study
from the Netherlands showed that most patients receive 5
days of postoperative antimicrobial therapy [22]. However,
it may be safe to stop intravenously administered (IV)
antibiotic treatment earlier than 5 days, when a patient
meets defined discharge criteria (patient is afebrile, has a
normal leukocyte count, has resumed oral intake) [10, 14,
23–29]. Cohort studies show that 3 days of postoperative
antibiotic treatment is feasible and safe [12, 30–32]. At
least 48 h of IV antibiotics is recommended in the Dutch
surgical guideline [15]. Small retrospective studies show
that even postoperative prophylaxis of less than 3 days is
feasible [33–36]. However, the methodological quality
of these studies is poor. Therefore, no definite recom-
mendations can be made regarding the optimum duration
of postoperative prophylaxis after appendectomy for
complex appendicitis. To date, no randomized clinical trial
has been published to address this topic in an adequately
powered study population.
Furthermore, there is a growing global health issue of
bacterial resistance. Antimicrobial resistance is a natural
biological outcome of antibiotic use and antibiotic over-
treatment speeds up this process [37]. Hence, restricting
antibiotic therapy is warranted, as pointed out in a report
by the World Health Organization [38]. This study aims
to evaluate efficacy of a restrictive postoperative antibiotic
course as compared to standard regimen for complex
appendicitis, in a non-inferiority design. This manuscript is
prepared in accordance with the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
guidelines [39].
Trial objective and hypothesis
The primary objective of this study is to evaluate the effi-
cacy and safety of discontinuing antibiotic treatment after
48 h, compared to completing a standard course of 5 days
after appendectomy for complex acute appendicitis. It is
hypothesized that a 48-h course is non-inferior to 5 days
and will not result in an increase of infectious complica-
tions and mortality. Secondary aims are to evaluate length
of hospital stay and cost-effectiveness.
Methods
Trial design
The Antibiotics following aPPendectomy In Complex
appendicitis (APPIC) trial is a phase IV, prospective,
multicenter, non-blinded, randomized controlled trial
powered for non-inferiority. Patients are randomly allocated
to a short course of 48 h (intervention arm), or the standard
course of 5 days (control arm) of IV antibiotics following
appendectomy for complex appendicitis. An overview of
enrollment, interventions, and follow-up of participants
in the APPIC trial is shown in Fig. 1. Figure 2 shows
the Standard Protocol Items Recommendations for
Interventional Trials (SPIRIT) Figure. The SPIRIT Checklist
is shown in Additional file 1.
Trial setting
The trial will run in at least 14 hospitals in the
Netherlands. This includes one academic hospital and
13 teaching hospitals. The participating hospitals are
listed on the trial webpage (www.appictrial.nl). In all
participating hospitals appendectomy is mostly performed
laparoscopically.
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Fig. 1 APPIC flowchart of inclusion and randomization. Legend: * All except intraoperative criteria regarding type of appendicitis; ** If the patient has
not been able to give informed consent prior to appendectomy, this may still be acquired postoperatively, as long as inclusion and randomization
takes place within 24 h; *** Intravenously administered antibiotic treatment continues for three more days to complete 5 days in total
Fig. 2 APPIC schedule of enrollment, interventions, and assessments
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Eligibility criteria
Patients of at least 8 years of age who are scheduled to
undergo surgery for suspected acute appendicitis will be
approached for participation in the study. If a complex
appendicitis is diagnosed intraoperatively, patients are
eligible for inclusion. A complex appendicitis is defined
as a gangrenous and/or perforated appendicitis or any
appendicitis in presence of an IAA [8]. Written informed
consent is preferably obtained before surgery, but may be
obtained postoperatively as long as inclusion and
randomization is performed within 24 h after surgery.
Exclusion criteria are:
 Unable to give informed consent (language barrier,
legally incapable)
 Interval appendectomy
 Clinical suspicion of severe sepsis*
 Conservative treatment of acute appendicitis
 American Society of Anesthesiologists (ASA) score
IV or not able to undergo surgery
 Known allergy or other contraindication to study
medication*
 Immunocompromised patients*
 Pregnancy
 Concurrent use of antibiotics for other indication*
 Simple acute appendicitis*
 Appendicular infiltrate not amendable for
appendectomy
 Inadequate source control in opinion of the
surgeon*
* more elaborate definitions are given in the full study
protocol.
Interventions
Postoperative antibiotic treatment
Participants will be randomized (1:1) to receive either:
(1) a short course of 48 h or (2) a standard 5-day course
of postoperative antibiotic treatment. All patients receive
IV antibiotics during the first 48 h after appendectomy:
cefuroxime/metronidazole (three times a day, 1500/500 mg),
or alternatively ceftriaxone/metronidazole (once a day,
2000 mg/three times a day, 500 mg) according to local
antibiotic policy. In the control group the IV antibiotics
are continued for three more days (a switch to an oral
formula is not allowed). A daily dose of gentamicin as
co-intervention is optional. No other antibiotics are
permitted.
Criteria for modifying the allocated treatment
Antibiotic treatment may be prolonged or restarted only in
case of a proven source of infection (a decision algorithm
is provided in the full protocol). A switch to a different
antibiotic regimen is allowed only if necessary due to an
adverse reaction to the antibiotics or if indicated by culture
results (if a micro-organism resistant to cefuroxime (or
ceftriaxone) is cultured a switch should be made to
ensure effective antibiotic treatment).
Discharge and follow-up
Laboratory tests, imaging studies, and blood cultures will
be performed only when clinically indicated. The following
clinical parameters will be registered on a daily basis: body
temperature < 38° Celsius, able to tolerate oral intake, able
to mobilize independently; Visual Analog Scale (VAS) < 4
requiring only orally administered analgesia. However,
these criteria are not mandatory for discharge and ultim-
ately the responsible physician decides when a patient is
able to go home. After discharge a standard outpatient visit
is planned at 2 to 4 weeks according to local hospital
policy. Four weeks after appendectomy, patients are asked
to complete a productivity-cost questionnaire. At 90 days
after appendectomy a standardized follow-up by telephone
will be conducted.
Outcome measures
All outcome measures will be registered directly from
the electronic patient files. Outcome assessors will not
be blinded for the treatment allocation. The telephone
follow-up is introduced to check missing data on the
primary endpoint; e.g., visits to hospitals or medical facilities
other than the center where the patient was treated and
included into the trial.
Primary outcome measure
The primary endpoint of this trial is a composite endpoint
of infectious complications related to appendectomy,
including IAA and surgical site infection (SSI), and
mortality within 90 days after appendectomy. An IAA
is defined as an infection that involves the abdominal
part of the body deeper than the fascial/muscle layers that
is opened or manipulated during the operative procedure.
IAA can be diagnosed through imaging or during reinter-
vention, through purulent drainage from a drain placed
into the IAA, or isolation of organisms from a culture of
the IAA [40]. An SSI can be either deep or superficial,
involving the skin, subcutaneous tissue and/or deep soft
tissues of the incision. IAA and SSI are defined in more
detail according to the Center for Disease Control (CDC)
criteria in the full study protocol [40].
Secondary outcome measures
Secondary endpoints are separate rates of IAA, SSI and
mortality; duration of antibiotic treatment; the antibiotic
regimen; proportion of patients that restarted antibiotics;
length of hospital stay (LOS); time to fulfill discharge
criteria; postoperative complications; reoperation; percutan-
eous drainage; number of visits to the general practitioner
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(GP), emergency room (ER) and outpatient clinic;
readmission rate; adverse events on antibiotics; and cost-
effectiveness. Complications will be classified according to
the Clavien-Dindo classification of surgical complications
as well as the Comprehensive Complication Index (CCI).
To analyze cost-effectiveness, the validated Institute for
Medical Technological Assessment – Productivity Cost
Questionnaire (iMTA-PCQ) (version October 2012) will be
used, enhanced with a section concerning school absence.
Sample size calculation
A power analysis was performed based on a one-sided
97.5% confidence interval for the effect of study arm
(intervention or control), an expected 15% primary end-
point rate and a 7.5% non-inferiority margin. To obtain
a power of 90%, 960 patients are needed (480 per treatment
arm). To account for possible effects of dropout and missing
data (10%) we will recruit 1066 patients. This sample
size should also yield sufficient power for the analysis
of secondary endpoints.
Recruitment
Recruitment of participants started on 12 April 2017
and is ongoing. Additional participating hospitals may be
recruited to ensure feasibility of the trial. The target of
1066 patients is expected to be completed in early 2020.
Allocation
Computerized block randomization (stratified for center)
will take place within 24 h after surgery through ALEA,
a web-based application managed by the Clinical Trial
Center (CTC) of the Erasmus MC. Random blocks of
different lengths are used. Eligible patients will be
randomized in a 1:1 ratio to arm A (short course) or
arm B (standard course). Each patient will be given a
unique study number. An independent data manager
from the CTC who is not involved with the clinical
practice or patient recruiting created the randomization
sequence. The result of the randomization and the patient
study number will immediately be provided through ALEA
per email to all parties predefined in the system who
should receive such notifications.
Implementation
Before the start of the trial, each center is visited by
the research team to inform and instruct the involved
personnel on study-specific procedures. Surgeons and
residents are trained how to assess the type of appendi-
citis to decide whether patients are eligible for study
participation by means of recorded examples of all
types of appendicitis.
Blinding
Blinding for treatment allocation in this study would
not only be difficult to achieve, but is also undesirable
because good clinical decision-making during the post-
operative course requires specific knowledge of antibiotics
that have or have not been given to the patient. Therefore,
this is an non-blinded trial.
Data collection and management
A data manager from each participating hospital will
carry out the data collection in collaboration with the
trial coordinator. Baseline demographics, as well as
preoperative, intraoperative and postoperative variables,
will be collected from the electronic medical records.
The validated iMTA-PCQ will be used for cost analysis.
A list of all variables is provided in the full study protocol.
All data will be entered into the secure online ALEA data-
base, a system validated and supported by the Erasmus
University Medical Centre. Data will be handled confiden-
tially and anonymously. A short intraoperative video or
static picture(s) should be recorded for quality assurance
of the diagnosis complex appendicitis. Quality control will
involve collecting data on adherence to the intervention,
patient inclusion and follow-up, as well as monitoring the
quality of the data entry. Qualified data managers of the
CTC of the Erasmus MC will perform quality control and
assurance. Checks and queries will be performed to
ensure quality, consistency, and completeness. Missing
data and inconsistencies will be reported back to the centers
to be clarified by the local responsible investigator.
Statistical analysis
We anticipate a 15% rate of infectious complications and
mortality in this study population. A 7.5% difference
(non-inferiority margin) in the primary endpoint rate is
deemed acceptable between the intervention group and
control group. This margin is considered acceptable
since mortality is expected to account for a negligible
proportion within the primary endpoint and infectious
complications after appendectomy can be well treated
with minimum morbidity and long-term consequences.
Primary endpoint
The study hypothesis will be tested by a one-sided 97.5%
confidence interval for the effect of study group (absolute
risk difference). This confidence interval will be adjusted
for effects of type of appendicitis and age (as a single
categorical covariate: < 16 years old/non-perforated, <
16 years old/perforated, ≥16 years old/non-perforated,
≥16 years old/perforated) using the method proposed by
Klingenberg [41, 42]. Non-inferiority will be established if
the upper limit of the confidence interval is lower than 7.5%.
Both per-protocol and intention-to-treat analyses will
be performed. In a secondary analysis, logistic regression
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analysis will be performed to identify predictors of the
composite primary endpoint. Independent variables in this
model will include treatment group and also age, sex,
surgical approach, type of appendicitis, ASA score, and
center, as well as significant interaction effects of these
independent variables with treatment group.
Secondary endpoints
General patient characteristics and other clinically relevant
parameters will be compared between the intervention
group and the control group with the independent samples
Student’s t test or the Mann-Whitney test in case of con-
tinuous outcome variables and the chi-square or Fisher’s
exact test in case of categorical outcome variables where
appropriate. All secondary endpoints will be compared
between the trial arms using linear regression for continu-
ous outcomes and logistic regression for dichotomous
outcomes, with adjustment for age, sex, surgical approach
(open versus laparoscopic), type of appendicitis, ASA
score, and center. In case of non-normally distributed
continuous outcomes, appropriate transformation of these
outcomes will be applied. A two-sided significance level of
0.05 will be used for all secondary analyses. Uncertainty
with respect to cost-effectiveness will be analyzed by boot-
strapping results for incremental costs and health effects.
The results will be shown in an acceptability curve that
indicates the probability that the intervention meets
several cost-effectiveness thresholds.
Data monitoring and safety
An independent safety committee (DSMB) is assembled
to monitor trial safety and progress, with special focus on
imbalance between the two trial arms in 90-day mortality
and serious postoperative complications. The DSMB is
composed of a statistician, two surgeons and a micro-
biologist, all of whom are unrelated to the study and have
no conflict of interest with the coordinating investigator
of the study. There will be two planned formal safety ana-
lyses: after the first 266 included patients have completed
follow-up and after 666 patients have completed follow-up.
Safety stopping rules will be applied using the alpha spend-
ing approach of O’Brien and Fleming, described into more
detail in the full study protocol. The DSMB will notify the
coordinating and principal investigators if conditions of the
stopping rules have been reached. The Steering Committee
will decide on continuation of the trial. The DSMB roles,
responsibilities, meetings and logistics are outlined in the
APPIC trial DSMB Charter.
Independent monitors of the CTC of Erasmus MC will
visit participating centers intervals at regular intervals to
verify adherence to the protocol and legal requirements
and perform source data verification. A first site moni-
toring visit will take place at each participating hospital
after the first three randomized patients have completed
follow-up. Subsequent monitoring visits will be planned
according to the predefined monitoring plan.
Rationale for the chosen study design
A non-inferiority design is chosen as the objective of this
trial is to show that a short course of antibiotics is no less
effective than a standard course, in terms of preventing
infectious complications. This is relevant in light of several
potential advantages of reduced use of antibiotics, such as
fewer adverse reactions to antibiotics, shorter length of
hospital stay, lower medical care costs and less antimicro-
bial resistance. In the academic literature, postoperative
infectious complications are reported in 15–20% of pa-
tients [43–45]. Furthermore, a similar study by Sawyer et
al. was aimed at detecting a 10% difference in complica-
tion rates after a shorter course of postoperative anti-
biotic treatment in complicated intra-abdominal
infections [28]. Based on these findings and the fact
that a reduction in antibiotic consumption will lead to
a significant reduction in costs and antimicrobial resist-
ance, we accept a 7.5% difference (non-inferiority margin)
in the primary endpoint rate. A non-inferiority trial with
this margin is acceptable based on the assumption that in-
fectious complications after an appendectomy for a com-
plex appendicitis are in general not associated with severe
morbidity and/or mortality. Since it is known that treat-
ment with IV antibiotics for 48 h ensures adequate tissue
concentrations (to eliminate the relevant micro-organisms
such as E. coli) [46–48], we have chosen 48 h of IV antibi-
otics as our intervention. For the individual patient ad-
vancing from the regular (3 to) 5 days of antibiotics
towards 48 h may not seem an enormous step forward.
However, extrapolating this to all patients with com-
plex appendicitis could have a major impact on health-
care. From a methodological perspective, we choose to
administrate antibiotics completely intravenously for
both the intervention and the control group. Some studies
found no support for use of orally administered antibiotics
after the initial postoperative intravenous administration
[26, 49]. In addition, it is questioned if adequate tissue
concentrations can be met by orally administered antibi-
otics for bacteria commonly isolated in complex appendi-
citis [50]. Complete intravenous courses will ensure
homogenous treatment in both study arms, without pa-
tients’ compliance or effectiveness of orally administered
antibiotics as uncertainties.
Discussion
The present study is designed to answer the question
whether 48 h of postoperative antibiotics is non-inferior
to the standard treatment of 5 days in patients with a
complex appendicitis. If non-inferiority is established,
this may lead to a reduction in the use of antibiotics in
the future. This in turn may shorten length of hospital
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stay and may result in lower hospital costs. In the longer
term, less use of antibiotics may slow down emergence
of antimicrobial resistance.
One of the five main objectives in the global action
plan on antimicrobial resistance by the World Health
Organization (WHO) is “to optimize the use of antimicro-
bial medicines” [51]. The global threat of antimicrobial
resistance urges for action against overuse. More research
is needed to determine the minimum effective courses for
many diseases. For several infections (e.g., pneumonia,
pyelonephritis, cellulitis) shorter courses have proven
just as effective as extended courses [52]. Yet, for many
diseases, including appendicitis, proper studies have
not been performed [53]. With a lifetime risk of about
7 to 8% and a pooled incidence of 100 to 151 per
100,000 person-years in the Western World, acute
appendicitis is one of the most common surgical emer-
gencies worldwide [1, 7, 8]. The 25 to 30% of complex
appendicitis represents a substantial number of patients
who receive prolonged antibiotic prophylaxis, as recom-
mended by the guidelines [15, 16, 18]. To date, no
randomized study has evaluated a reduced course of
postoperative antibiotics in an adequately powered study.
Some studies – all including pediatric patients – have
compared a course with a predefined minimum duration
(mostly 4 days) with a variable duration based on clinical
and laboratory parameters (body temperature < 38 °C,
resumed oral intake, white blood cell count) [14, 23–25, 32].
However, these clinical parameters may still cause overtreat-
ment with antibiotics, as an increased body temperature or
delayed clinical improvement may well reflect a prolonged
sterile SIRS response rather than an infectious focus [54].
Median antibiotic treatment duration was still 5 days in
most studies. Evidence for restricting postoperative antibi-
otics to less than 3 days after appendectomy is limited. Two
retrospective studies demonstrated that antibiotics for more
than 24 h after surgery for complex appendicitis does not
reduce the rate of infectious complications. Kimbrell et al.
[33] included eight patients that had received antibiotics for
24 h at most and 44 patients that had received antibiotics
for more than 24 h. Reported IAA rates were 25% and
20.5%, respectively (p = 1.00). In a larger study (n = 410)
by Kim et al. [35] multivariable regression analysis
revealed no difference in SSI rate between patients with
complex appendicitis that received postoperative prophy-
laxis (for a median of 7 days (range 2–21)) and patients
that did not. Unfortunately, IAA rate was not reported in
this study. Two more studies reported interesting results
of antibiotic treatment restricted to less than three postop-
erative days: no intra-abdominal abscesses occurred in 55
and 11 patients that received antibiotics for 24–48 h and
0–24 h, respectively [34, 36]. The small sample sizes and
retrospective nature of these studies must be recognized
when interpreting the results. Surgeons may be less
inclined to prolong prophylaxis in healthier patients
and more so in patients that are at increased risk of
complications.
Whereas evidence about the duration of postoperative
antibiotics for complex appendicitis is missing, this has
been evaluated in patients with intra-abdominal infections.
The STOP-IT trial investigated a restricted antibiotic
course after adequate source-control procedures for
complicated intra-abdominal infections [28]. Some 14%
of included patients had a complex appendicitis. After a
median duration of 4 days of antibiotics in the inter-
vention arm and 7 days in the control arm, infectious
complications occurred in 21.8% and 22.3% of the
groups, respectively (p = 0.92). Some critical notes can
be made. Premature closure of the study, due to concerns of
futility led to an underpowered study to demonstrate
equivalence of both regimens. Also, in a large proportion of
patients (23%) the protocol-specified treatment duration
was not adhered to [55]. On the other hand, both intention-
to-treat and per-protocol analyses were performed and the
rate of complications above 20% in both groups confirms
that antibiotics may not have a significant role in prevention
of infectious complications at all [56].
More recently the PEANUTS trial was published: a
multicenter randomized controlled trial of extended
(3 days) versus single-dose antibiotic prophylaxis for
(mild) acute calculous cholecystitis [57]. Similar rates of
postoperative infectious complications were seen in both
groups (4%). As for complex appendicitis, the recom-
mended duration of antimicrobial therapy varies in guide-
lines and there is a lack of randomized trials. In line with
results from the STOP-IT trial, no benefit was found for
extending postoperative prophylaxis, in a randomized
setting. Subsequently, the PEANUTS-II trial started
(Dutch Trial Register no. NTR5802), in which patients
with (mild) acute calculous cholecystitis are randomized
to single-dose perioperative prophylaxis or no antibiotic
prophylaxis at all.
A nationwide prospective cohort study from the
Netherlands in 2014 showed that in most patients (78%)
antibiotics were given for 5 days or more after surgery for
complex appendicitis. The authors concluded that 3 days of
antibiotics led to a similar rate of infectious complications.
Surgical site infections and intra-abdominal abscesses were
seen in 1.3% and 1.6% (p = 0.89) and 8.0% and 8.9% of
patients (p= 0.81), respectively [30]. In Denmark, postoper-
ative prophylaxis of 3 days has become standard care
already [58]. Moreover, in several hospitals in the UK 24 h
(three doses) of antibiotics has been introduced.
Two limitations of this study should be mentioned.
Firstly, the present study is non-blinded. Blinding for
treatment allocation would require patients in arm A
(48 h) to remain admitted to the hospital and receive a
placebo drug intravenously for 3 days. This would put a
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significant strain on length of hospital stay and costs for
the participating hospitals. More importantly, in terms
of good clinical decision-making it is important for the
treating physician to know whether or not the patient is
still receiving actual antibiotics. It is important to reduce
risk of bias wherever possible, yet blinding in this trial
would not be feasible or desirable. Another limitation is
the diagnosis of complex appendicitis which can be rather
subjective and dependent on individual surgeons’ opinions
[59]. As we strived for this trial to follow clinical practice,
we chose to keep the definition of complex appendicitis
simple (a gangrenous and/or perforated appendicitis or
appendicitis in presence of intra-abdominal abscess) and
to rely on the surgeon’s intraoperative judgement. For
quality assurance, a static image or video of the appen-
dicitis is taken for patients included in the APPIC trial.
This way, we will be able to assess the reliability and
reproducibility of the diagnosis afterwards.
Trial status
Trial registries: EudraCT 2016–003428-21, issued on 16
August 2016. Dutch trial register (NTR) no. 6128, registered
on 20 December 2016. The first investigators’ meeting took
place on 3 April 2017. Twelve centers have been initiated
and are actively recruiting. The first patient was included on
9 June 2017. In total, 165 patients were randomized, while
this manuscript was being completed. Recruitment is
expected to end in early 2020.
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